SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial

Trück, J; Snape, MD; Tatangeli, F; Voysey, M; Yu, LM; Faust, SN; Heath, PT; Finn, A; Pollard, AJ (2014) Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. PLOS ONE, 9 (3). e91413 (1) - e91413 (11). ISSN 1932-6203 https://doi.org/10.1371/journal.pone.0091413
SGUL Authors: Heath, Paul Trafford

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Available under License St George's repository terms & conditions.

Download (758kB) | Preview

Abstract

Background: In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7) or 13- valent (PCV-13) pneumococcal conjugate vaccine at 2, 4 and 12 months of age. At 13 months of age, most of these children had pneumococcal serotype-specific IgG concentrations $0.35 mg/ml and opsonophagocytic assay (OPA) titers $8. Methods: Children who had participated in the original study were enrolled again at 3.5 years of age. Persistence of immunity following infant immunization with either PCV-7 or PCV-13 and the immune response to a PCV-13 booster at preschool age were investigated. Results: In total, 108 children were followed-up to the age of 3.5 years and received a PCV-13 booster at this age. At least 76% of children who received PCV-7 or PCV-13 in infancy retained serotype-specific IgG concentrations $0.35 mg/ml against each of 5/7 shared serotypes. For serotypes 4 and 18C, persistence was lower at 22–42%. At least 71% of PCV-13 group participants had IgG concentrations $0.35 mg/ml against each of 4/6 of the additional PCV-13 serotypes; for serotypes 1 and 3 this proportion was 45% and 52%. In the PCV-7 group these percentages were significantly lower for serotypes 1, 5 and 7F. A pre-school PCV-13 booster was highly immunogenic and resulted in low rates of local and systemic adverse effects. Conclusion: Despite some decline in antibody from 13 months of age, these data suggest that a majority of pre-school children maintain protective serotype-specific antibody concentrations following conjugate vaccination at 2, 4 and 12 months of age. Trial Registration: ClinicalTrials.gov NCT01095471

Item Type: Article
Additional Information: Copyright: 2014 Truck et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, MULTIDISCIPLINARY SCIENCES, STREPTOCOCCUS-PNEUMONIAE, CONJUGATE VACCINATION, UNITED-KINGDOM, OTITIS-MEDIA, CHILDREN, CARRIAGE, BOOSTER, IMMUNOGENICITY, REPLACEMENT, DISEASE, General Science & Technology, MD Multidisciplinary
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: PLOS ONE
ISSN: 1932-6203
Related URLs:
Dates:
DateEvent
11 March 2014Published
Web of Science ID: WOS:000332842400088
URI: https://openaccess.sgul.ac.uk/id/eprint/107050
Publisher's version: https://doi.org/10.1371/journal.pone.0091413

Actions (login required)

Edit Item Edit Item